NAS:PODD (USA)
Business Description
Insulet Corp
NAICS : 339112
SIC : 3841
100 Nagog Park, Acton, MA, USA, 01720
Description
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the U.S. Food and Drug Administration in 2005, approximately 150,000 insulin-dependent diabetics are using it worldwide.
Financial Strength
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.5 | |||||
Equity-to-Asset | 0.2 | |||||
Debt-to-Equity | 3.34 | |||||
Debt-to-EBITDA | 9.53 | |||||
Interest Coverage | 2.07 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 7.45 | |||||
Beneish M-Score | -1.28 | |||||
WACC vs ROIC |
Growth Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 20.1 | |||||
3-Year EBITDA Growth Rate | 37 | |||||
3-Year EPS without NRI Growth Rate | 68.7 | |||||
3-Year FCF Growth Rate | -10.3 | |||||
3-Year Book Growth Rate | 30.9 | |||||
Future 3-5Y EPS without NRI Growth Rate Industry Rank | 133.23 | |||||
Future 3-5Y Total Revenue Growth Rate Industry Rank | 16.51 |
Momentum Rank
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 57.95 | |||||
9-Day RSI | 63.69 | |||||
14-Day RSI | 64.22 | |||||
6-1 Month Momentum % | -3.54 | |||||
12-1 Month Momentum % | -23.3 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 4.69 | |||||
Quick Ratio | 3.54 | |||||
Cash Ratio | 2.53 | |||||
Days Inventory | 270.73 | |||||
Days Sales Outstanding | 47.81 | |||||
Days Payable | 49.37 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -5.3 |
Profitability Rank
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 68.07 | |||||
Operating Margin % | 8.03 | |||||
Net Margin % | 2.94 | |||||
ROE % | 7.26 | |||||
ROA % | 1.7 | |||||
ROIC % | 7.17 | |||||
ROC (Joel Greenblatt) % | 10.56 | |||||
ROCE % | 4.87 | |||||
Years of Profitability over Past 10-Year | 4 |
GF Value Rank
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 542.64 | |||||
Forward PE Ratio | 211.05 | |||||
PE Ratio without NRI | 542.64 | |||||
PEG Ratio | 3.91 | |||||
PS Ratio | 16.19 | |||||
PB Ratio | 44.57 | |||||
Price-to-Tangible-Book | 59.63 | |||||
EV-to-EBIT | 223.02 | |||||
EV-to-Forward-EBIT | 614.18 | |||||
EV-to-EBITDA | 131.9 | |||||
EV-to-Forward-EBITDA | 111.3 | |||||
EV-to-Revenue | 16.57 | |||||
EV-to-Forward-Revenue | 15.59 | |||||
EV-to-FCF | -136.41 | |||||
Price-to-Median-PS-Value | 1.77 | |||||
Price-to-Peter-Lynch-Fair-Value | 21.71 | |||||
Price-to-Graham-Number | 37.95 | |||||
Earnings Yield (Greenblatt) % | 0.46 | |||||
Forward Rate of Return (Yacktman) % | 19.47 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Gurus Latest Trades with NAS:PODD
Executives
EMBED
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 1,178.1 | ||
EPS (TTM) ($) | 0.5 | ||
Beta | 0.85 | ||
Volatility % | 28.63 | ||
14-Day RSI | 64.22 | ||
14-Day ATR ($) | 9.395138 | ||
20-Day SMA ($) | 255.7725 | ||
12-1 Month Momentum % | -23.3 | ||
52-Week Range ($) | 181 - 324.81 | ||
Shares Outstanding (Mil) | 69.4 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 5 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Insulet Corp Filings
Document | Form | Filing Date | ||
---|---|---|---|---|
No Filing Data |